| INTRODUCTION
Standard therapy for patients with primary renal cell carcinoma (RCC) is surgery; in particular, partial nephrectomy has shown high efficacy with low complication rates, compared with radical nephrectomy, for localized RCC. 1 Alternative treatment options for stage Ia RCC patients include ablation therapies such as cryoablation and radiofrequency ablation when active surveillance is not selected. [1] [2] [3] [4] [5] In contrast, there is no standard radical therapy for primary RCC patients who are ineligible for surgery or ablation.
Until recently, radiotherapy has not been used to treat primary RCC, because this cancer is thought to be poorly sensitive to radiation. As a result of recent improvements in radiotherapy techniques, X-ray stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR) provide highly focused hypofractionated irradiation of tumors. These novel radiotherapy techniques have shown favorable local control rates (97.8%-100% at 2 years) and few severe adverse events. [6] [7] [8] [9] However, to the best of our knowledge, there are no long-term follow-up data of SBRT/SABR for primary RCC.
Carbon-ion radiotherapy (CIRT) has notable characteristics in both physics and biology: it limits irradiation to the target volume with little effect on surrounding healthy tissue, and shows strong cytotoxicity as a result of high linear energy transfer, unlike the X-ray beam. 10, 11 The Hospital of the National Institute of Radiological Sciences began using CIRT to treat primary RCC in 1997. We previously reported a pilot study involving 10 primary RCC patients treated with CIRT, and the results showed high local control rates (100% at 5 years) with few adverse events, even in the inoperable patients. 12 However, one limitation of our previous study was that only 4 patients were followed up for 5 years or longer, limiting the amount of information on late adverse events and RCC recurrence/ mortality rates. The purpose of the current study is to clarify the late adverse events of CIRT, including renal function, and the secondary objective is to evaluate long-term treatment effects, based on updated data on the long-term outcomes of CIRT carried out at our institution. was set as the starting dose. Diagnosis was confirmed using computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography, angiography, and needle biopsy; however, biopsy was not carried out if the radiographical findings were typical of RCC.
| MATERIALS AND METHODS

| Study design
The TNM Classification of Malignant Tumors (seventh edition) was used for tumor staging. 13 These 19 treatments were conducted in accordance with the ethical standards set forth by the Declaration of Helsinki, 14 and all patients satisfying the enrollment criteria were approved by the ethics committee.
| Treatment
The treatment method as well as the physical and biological characteristics of CIRT have been described in previous studies. 12 Briefly, the irradiation fields were established using a 3-D planning system based on 2.5-5-mm-thick CT images. Gross tumor volume was 
| Follow up
Each patient was examined using blood tests, ultrasonography, dynamic contrast-enhanced CT, and MRI according to the European Society of Urogenital Radiology guidelines, 15 at least once every 3 months for the first 6 months and then usually every 6 months thereafter.
To evaluate kidney toxicity, estimated glomerular filtration rate (eGFR) was calculated in all cases according to the formula reported by Matsuo et al. 16 Kidney function as well as other adverse events were evaluated according to the National Cancer Institute's Common 
| Evaluation
Evaluation of eGFR was conducted from pre-CIRT to the end of follow up or to the start of dialysis. Local failure was defined as either progressive disease according to the modified response evaluation criteria in solid tumors 18 
| Statistics
Cumulative local control rate and disease-free, cancer-specific, and overall survival rates were calculated using the Kaplan-Meier method. Log-rank test was used to compare the cancer-specific survival rates. P-value <0.05 was considered significant. All statistical analyses were carried out using IBM SPSS Statistics, version 20 (IBM Japan, Ltd, Tokyo, Japan).
| RESULTS
Patient, tumor, and treatment characteristics of the 19 patients are shown in Table 2 . The first 10 patients (#1-10) are the same as those reported previously. 12 Median tumor size was 36 (range, 24-120) mm.
Of the 19 patients, 11 were diagnosed by radiographic findings.
Biopsy was carried out in 8 patients, all of whom were diagnosed with clear cell carcinoma. Of the treatments received prior to CIRT, 2 advanced-stage patients (#3 and #10) received interferon-α (IFN-α), but a treatment response was not observed. 12 CIRT was delivered to the thoracic vertebra (64 Gy 
| Adverse events
Chronic kidney disease grades of the 19 patients pre-CIRT versus at the end of follow up are shown in Table 3 . Of the 7 patients with grade 2 or higher CKD pre-CIRT, 4 had progressed to grade 4 by the end of follow up. 
| Recurrence and survival
Other treatments for RCC were not carried out post-CIRT until detection of recurrence, except for patient #3 with stage IV RCC at presentation who was treated with IFN-α. As of March 2018, local failure was observed in 2 patients and distant failure in the lung and bone in 5 patients after CIRT (prognosis of patient #3 after 6.1 years post-CIRT is unknown; Table 2 ). The following treatments were given after recurrence: IFN-α in 2 patients (#6 and #12), interleukin-2 in 1 (#9), molecular targeted therapy in 3 (#9, #10, and #14), and CIRT (60 Gy [RBE]/4 fractions for lung metastasis) in 1 patient (#10).
By the end of follow up, 11 patients were alive and 8 patients were dead, including 4 deaths due to progressive RCC (Table 2) . 
| DISCUSSION
The 19 primary RCC patients treated with CIRT at our institution, including 9 inoperable patients with comorbidities and advanced Pt., patient; M, male; F, female; CIRT, carbon-ion radiotherapy; RBE, relative biological effectiveness; fr., fraction; RCC, renal cell carcinoma; COPD, chronic obstructive pulmonary disease. Otherwise, few grade 2 or higher adverse events were observed.
Surely the skin and subcutaneous tissue are important organs at risk of late radiation-induced morbidities after charged particle therapy because of lack of build-up at the beam entrance. 10 Mean.
The present study showed relatively favorable 5-year local control and cancer-specific survival and overall survival rates, even in those 9 cases deemed inoperable because of advanced stage or comorbidities. There were limitations to the present study. First, this study was retrospectively conducted at a single institution and consisted of a limited number of patients; a multi-institutional prospective study with long-term follow-up data is needed to definitively determine the provisional efficacy of CIRT for RCC, followed by randomized control trials. Second, imaging diagnoses were carried out without biopsy for 11 of the 19 patients in the pooled cohort. Although imaging diagnoses were conducted by more than 1 radiologist in this study, discrepancies between imaging and pathological results are possible 30, 31 and, treatment effect therefore may have been overestimated.
In conclusion, this retrospective study with updated long-term follow-up data suggests that CIRT is a safe treatment option for RCC patients without definitive renal comorbidities, yielding favorable treatment outcomes even in inoperable cases.
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